Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis.
Fiche publication
Date publication
novembre 2014
Journal
BMC neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Manceau P, Latarche C, Pittion S, Edan G, de Sèze J, Massart C, Debouverie M
Lien Pubmed
Résumé
The clinical impact of neutralizing antibodies against interferon-beta (NAb) is controversial. Their presence can lead to a decrease in interferon-beta (IFNβ) efficacy. Fatigue reported in patients with multiple sclerosis (MS) may be associated with an unfavorable clinical course. We conducted a prospective multicentre study to assess the association between response to IFNβ, NAb and fatigue.
Mots clés
Adult, Antibodies, Neutralizing, blood, Biomarkers, analysis, Fatigue, etiology, Female, Humans, Interferon-beta, therapeutic use, Male, Multiple Sclerosis, Relapsing-Remitting, drug therapy, Prospective Studies
Référence
BMC Neurol. 2014 Nov 30;14:215